Clinical Trials Logo

Tobacco Use clinical trials

View clinical trials related to Tobacco Use.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06442384 Not yet recruiting - Tobacco Use Clinical Trials

Remote Trial - Tobacco Product Standard (VLNC)

Start date: November 1, 2024
Phase: N/A
Study type: Interventional

The goal of this pilot project is to explore the feasibility of a real-world marketplace study design examining the effects of a reduced nicotine product standard for cigarettes on smoking in the context of a flavor restriction vs. no restriction on e-cigarettes in smokers switched to very low nicotine content cigarettes.

NCT ID: NCT06372899 Not yet recruiting - Tobacco Use Clinical Trials

Alternative Nicotine Delivery Systems as Potential Harm Reduction Tools for Persistent Cigarette Smokers

Start date: July 2024
Phase: N/A
Study type: Interventional

This between-subjects study aims to evaluate whether e-cigarettes (ECIGS) versus oral nicotine pouches (ONPS) more readily substitute for combustible cigarettes among 200 cigarette smokers. After measuring baseline cigarette smoking rate, participants will be randomized to ECIGS or ONPS and be instructed to switch (versus smoking cigarettes) over a 6-week period. Relative reductions in biomarkers of exposure will be measured. ECIG- and ONP-associated subjective reward and the reinforcing value of ECIGS and ONPS relative to combustible cigarettes will be assessed as mechanisms.

NCT ID: NCT06310187 Not yet recruiting - Oxidative Stress Clinical Trials

Little Cigar Oxidants

Start date: July 2024
Phase: N/A
Study type: Interventional

Determine the effects of little cigars on human exposure to tobacco smoke oxidants. In a balanced randomized cross-over study design in cigarette smokers, subjects will be assigned to 6 exposure groups. These include a high oxidant unflavored little cigar exposure condition, a low oxidant unflavored little cigar exposure condition, a high oxidant flavored exposure condition, a low oxidant flavored exposure little cigar exposure condition, their usual cigarette, and a control condition (unlit little cigar). Following the smoking of each product, exhaled breath condensate samples will be collected at baseline, 30, 60, 90, 120 and 150 minutes. Samples will be analyzed for levels of oxidant markers including hydrogen peroxide, 8-isoprostanes, and C-reactive protein, as well as nicotine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and N'-nitrosonornicotine (NNN).

NCT ID: NCT06303115 Not yet recruiting - Smoking Clinical Trials

CSD231005 Nicotine Pouch Biomarkers of Exposure

Start date: July 15, 2024
Phase: N/A
Study type: Interventional

This will be a multi center open label, randomized, controlled, switching parallel-group study designed to assess changes in select biomarkers of exposure (BoE) in generally healthy smokers following a 5 day in-clinic switch to use of nicotine Pouch investigational products (IPs) compared to continued usual brand (UB) cigarette smoking or smoking abstinence.

NCT ID: NCT06295757 Not yet recruiting - Nicotine Dependence Clinical Trials

Effects of Relighting on Smoke Toxicant Deliveries and Subjective Smoking Measures

Start date: July 1, 2024
Phase: N/A
Study type: Interventional

Characterize effects of relighting on smoke toxicant deliveries and subjective smoking measures. This will be a within-subject comparison in a single experimental group of 30 smokers who report engaging in relighting behaviors. We will assess smoking intensity for relit and non-relit (i.e., smoked continuously without relighting) cigarettes in the natural environment and will conduct in-clinic measurements of smoking topography and subjective responses for relit and non-relit cigarettes. Information on relighting patterns and smoking topography collected from each participant will be used to compare machine-measured smoke yields of key harmful constituents when their usual cigarettes are smoked with and without relighting. Hypothesis: Relit cigarettes will produce higher levels of toxicants than non-relit cigarettes.

NCT ID: NCT06264154 Not yet recruiting - Smoking Clinical Trials

The Role of Flavor in the Substitutability of E-cigarettes for Combustible Cigarettes Among Persistent Smokers

Start date: July 2024
Phase: N/A
Study type: Interventional

This between-subjects study aims to evaluate the effect of flavor on initial and sustained switching from combustible cigarettes to e-cigarettes among 210 cigarette smokers. After measuring baseline cigarette smoking rate, participants will be randomized to a six-week regimen of fruit-flavored, tobacco-flavored, or menthol-flavored e-cigarettes and be instructed to switch (versus smoking cigarettes) over a 6-week period. Flavor-associated subjective reward and the reinforcing value of flavored e-cigarettes relative to combustible cigarettes will be assessed as mechanisms.

NCT ID: NCT06234722 Not yet recruiting - Tobacco Use Clinical Trials

Modeling Tobacco Regulatory Impacts in Appalachia Using the Experimental Tobacco Marketplace

Start date: June 1, 2024
Phase: N/A
Study type: Interventional

The goal of this project is to look at the effect of proposed tobacco product regulations in Appalachian Kentucky. Appalachian Kentucky is a diverse and underserved rural area that would benefit from more tobacco regulation research. Researchers will study the effects of three proposed tobacco product regulations among users of tobacco products in Appalachian KY. Researchers will also study how degree of rurality effects how those regulations impact behavior. Participants will be asked to complete online surveys and tests, online shopping sessions in a simulated Experimental Tobacco Marketplace, and track their tobacco product use throughout the 9-week experiment.

NCT ID: NCT06074939 Not yet recruiting - Tobacco Use Clinical Trials

FRESHAIR4Life: Building the Case for Action

Start date: October 2023
Phase:
Study type: Observational

The goal of this observational study is to understand the burden and determinants of tobacco use and air pollution (AP) exposure among mid- to late adolescents in Greece, the Kyrgyz Republic, Pakistan, Romania, and Uganda. This context-specific knowledge will be crucial for selecting, adapting, and implementing preventive interventions in the next phase of the project. The main questions the investigators aim to answer are: - What is the perceived burden of tobacco use and AP exposure among adolescents? - What are the contextual drivers and behavioral determinants contributing to (prevention of) these risk factors? - How do the dynamics between stakeholders influence prevention efforts? In this study, data will be collected through interviews, focus group discussions, photovoice, document analysis, observations, personal exposure monitoring, and questionnaires.

NCT ID: NCT05999383 Not yet recruiting - Tobacco Use Clinical Trials

Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration

CANNIC
Start date: October 31, 2023
Phase: Phase 2
Study type: Interventional

This is a crossover, randomized, double-blinded clinical pharmacology study enrolling dual cannabis-tobacco smokers to better understand the combined effects of co-administering cannabis and tobacco. The project aims to describe the pharmacokinetics and pharmacodynamics of marijuana-tobacco co-administration by delivering THC and nicotine in various combinations. This foundational study will establish a research program focused on elucidating the public health consequences of marijuana-tobacco co-use.

NCT ID: NCT05612152 Not yet recruiting - Tobacco Use Clinical Trials

Choose2Quit: Improving Equity in Smoking Cessation for Low Income Adults

Start date: November 1, 2022
Phase: N/A
Study type: Interventional

The goal of this study is to evaluate the effectiveness of a tobacco treatment navigator to improve primary care patient engagement in tobacco cessation support. We compare an ask, advise and connect to the quitline approach vs. the novel tobacco treatment navigator approach on the primary outcomes of receipt of tobacco cessation counseling sessions and receipt of tobacco cessation medications.